Ecnoglutide Cuts Adolescent BMI by Up to 12.6% in Phase 1b
Sciwind Biosciences reported that 20 weeks of ecnoglutide treatment reduced BMI by up to 12.6% and body weight by up to 12.1% among adolescents with obesity in a phase 1b trial.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
HK inno.N said its Chinese partner Sciwind Biosciences presented the phase 1b findings at the European Association for the Study of Diabetes meeting in Milan on September 30. The trial enrolled 48 Chinese adolescents aged 12 to 17 with obesity.
What the early trial found
Sciwind Biosciences found that participants receiving ecnoglutide for 20 weeks had reductions of up to 12.6% in BMI and up to 12.1% in body weight. Ecnoglutide is a GLP-1 receptor agonist designed with biased signaling through cyclic adenosine monophosphate.
These efficacy figures come from an early phase 1b study involving 48 Chinese adolescents aged 12 to 17. The small, specific study population limits how confidently the findings can be applied to other adolescents or used to predict results in broader clinical practice.
HK inno.N's connection to the drug
HK inno.N licensed ecnoglutide from Sciwind Biosciences in 2024. Sciwind Biosciences conducted the adolescent study and presented its findings.
Frequently asked questions
How much did ecnoglutide lower BMI in adolescents?
Sciwind Biosciences reported a reduction of up to 12.6% after 20 weeks. This result came from a phase 1b trial of 48 Chinese adolescents aged 12 to 17, so it carries uncertainty beyond that small and specific population.
How much weight did participants lose after 20 weeks?
Sciwind Biosciences reported a body-weight reduction of up to 12.1%. The figure describes an early clinical trial result and should not be treated as a prediction for every adolescent.
Who participated in the ecnoglutide adolescent trial?
Sciwind Biosciences enrolled 48 Chinese adolescents aged 12 to 17 with obesity in the phase 1b study.
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
